

M1 Kliniken AG

Germany / Healthcare Facilities & Services
 Frankfurt
 Bloomberg: M12 GR
 ISIN: DE000A0STSQ8

Update following
 capital increase

RATING
PRICE TARGET
 Return Potential
 Risk Rating

BUY
€ 16.50
 44.7%
 High

PRICE TARGET RAISED ON SUCCESSFUL EXPANSION OF CLINIC NETWORK

M1 Kliniken AG (M1) has raised new capital of €16.5m through the placement of €1.5m shares at €11.0 each. The placement process was accelerated due to oversubscription. The company intends to use the proceeds to finance faster expansion of its clinic network. H1 2017 results published two months ago were strong and came in ahead of our expectations. Due to the expansion of the clinic network across Germany, H1 sales, operating profit (EBIT) and net income showed significant increases y/y. Sales grew 20% to €22.3m (FBe: 22.0m) and the operating margin widened to 18.7% (FBe: 15.0%). We believe management intends to capitalize on this strong momentum. We anticipate that M1 will grow faster than we had previously projected and are upgrading our sales and EBIT estimates for the period 2017 and beyond. In addition, we believe the operational risk has declined over the last half year. We have consequently lowered our WACC estimate by 1.5 percentage points to 10.5% (previously: 12.0%). Our updated DCF-model now yields a price target of €16.50 (previously: €10.80). Our rating remains Buy.

H1 2017 sales were slightly better than expected H1 2017 sales increased by 20% y/y to €22.3m (FBe: €22.0m; H1/16: €18.5m). M1's sales growth was driven by the aggressive expansion of clinics across Germany, which totalled 13 at the end of June 2017. The company is currently in the process of opening an additional outpatient clinic in Leipzig. In addition, in May 2017, the company acquired a 2,000 square metre building in the centre of Essen, which has the potential to nearly double the surgical capacity available in the main clinic in Berlin-Köpenick. As a result, management is confident about future growth prospects and has reiterated guidance of 20% sales growth in FY 2017.

Strong EBIT was ahead of our expectations H1/17 EBIT surged 36% y/y to €4.2m (FBe: €3.3m; H1/16: €1.0m). This implies an increase in the EBIT margin to 18.7% (FBe: 15.0%) in H1/17 from 16.5% in the prior year period.

p.t.o.

FINANCIAL HISTORY & PROJECTIONS

	2014	2015	2016	2017E	2018E	2019E
Revenue (€m)	23.02	34.93	35.96	44.76	58.19	74.49
Y-o-y growth	278.5%	51.7%	2.9%	24.5%	30.0%	28.0%
EBIT (€m)	5.02	7.01	4.36	6.31	7.91	10.43
EBIT margin	21.8%	20.1%	12.1%	14.1%	13.6%	14.0%
Net income (€m)	4.59	6.63	5.01	6.33	7.25	9.27
EPS (diluted) (€)	0.31	0.44	0.33	0.41	0.44	0.56
DPS (€)	0.00	0.30	0.30	0.27	0.30	0.33
FCF (€m)	-5.96	0.70	9.91	6.39	4.41	5.68
Net gearing	-1.5%	-1.3%	-19.2%	-49.8%	-46.9%	-44.5%
Liquid assets (€m)	2.40	0.41	5.81	24.17	24.07	24.78

RISKS

Risks include, but are not limited to the ability to retain management and key medical staff, legal and market risks.

COMPANY PROFILE

M1 Kliniken AG is a provider of aesthetic medical procedures. The company is headquartered in Berlin, has an extensive footprint with 14 beauty clinics in Germany and is striving to become a leading player in Europe. M1 provides a comprehensive range of medical aesthetic treatments such as liquid lifting (e.g. application of Botox) and plastic surgery at competitive prices.

MARKET DATA

As of 31 Oct 2017

Closing Price	€ 11.40
Shares outstanding	16.50m
Market Capitalisation	€ 188.18m
52-week Range	€ 7.75 / 11.93
Avg. Volume (12 Months)	3,151

Multiples	2016	2017E	2018E
P/E	34.1	27.7	26.0
EV/Sales	5.1	4.1	3.2
EV/EBIT	42.3	29.3	23.3
Div. Yield	2.6%	2.4%	2.6%

STOCK OVERVIEW



COMPANY DATA

As of 30 Jun 2017

Liquid Assets	€ 3.47m
Current Assets	€ 15.07m
Intangible Assets	€ 8.22m
Total Assets	€ 32.13m
Current Liabilities	€ 2.69m
Shareholders' Equity	€ 29.45m

SHAREHOLDERS

MPH Mittelständ. Pharma Holding AG	75.8%
Free Float	24.2%



The H1/17 EBIT margin benefited from a strong gross margin of 44.6% (FBe: 40.0%, H1/16: 58.3%) due to greater than expected economies of scale. Net income for the period came in at €3.7m (FBe: €2.9m; H1/16: €2.9m), boosted by the strong EBIT. EPS was €0.25 (FBe: €0.19; H1/16: €0.19).

Figure 1: Six month results vs. FB estimates

All figures in EUR '000	H1/17	H1/17E	Delta	H1/16	Delta
Revenue	22,257	22,000	1%	18,498	20%
Operating income (EBIT)	4,157	3,300	26%	3,046	36%
margin	18.7%	15.0%		16.5%	
Net income / loss	3,688	2,900	27%	2,893	27%
margin	16.6%	13.2%		15.6%	
EPS (in EUR, dil.)	0.25	0.19	27%	0.19	27%

Source: First Berlin Equity Research, M1 Kliniken AG

Positive operating cash flow; free cash flow was lower due to acquisition of building in Essen

Operating cash flow came in at €4.2m (H1/16: €40m). Cash flow from investment activities increased substantially to €2.0m (H1/16: €-0.5m), due to the acquisition of a building for the new clinic in Essen, while H1/16 numbers were helped by the cash inflow from disposal of financial assets. As a result, free cash flow (operating cash flow minus CAPEX) declined to €2.2m (H1/16: €4.5m). Due to dividend payments of €4.5m, net cash flow was negative at €-2.3m (H1/16: €0.0m).

H1/17 balance sheet remains stable M1 reported a cash position of €3.5m (FY/16: €5.8m). Inventories decreased slightly to €1.3m (FY/16: €1.4m). Tangible assets increased to €2.8m from €1.0m in FY/16, mainly as a result of the purchase of the building in Essen. Equity declined slightly to €29.4m (FY/16: €30.3m) but the equity ratio was still very high at 92% (FY/16: 94%).

Estimates revised upward due to strong H1/17 operating result and our expectation of sales growth acceleration from 2018

Given the improved EBIT performance in H1/17, we expect a stronger FY/17 and have upgraded our EBIT forecast for FY/17. We have changed some of our FY/17 cost estimates based on the H1/17 results. M1 is hiring and training staff aggressively. Personnel expenses equalled 14.9% of sales in H1/17. We have therefore increased our personnel cost estimate to 15.0% of sales (previously: 10.6%). At the same time, we have reduced our COGS estimate. The net effect of these changes is a rise in our 2017 EBIT margin forecast from 13.3% to 14.1%. M1 has substantially strengthened its cash position through the recent capital increase thereby gaining the financial strength required to accelerate ongoing expansion. We have therefore increased our sales forecast for 2018 and beyond as summarized in figure 2 below.

Figure 2: Changes to our forecasts (KPIs)

All figures in EUR '000	2017E			2018E			2019E		
	Old	New	% change	Old	New	% change	Old	New	% change
Revenue	44,764	44,764	0.0%	52,822	58,193	10.2%	60,217	74,488	23.7%
Operating income (EBIT)	5,954	6,312	6.0%	7,342	7,914	7.8%	9,574	10,428	8.9%
margin	13.3%	14.1%		13.9%	13.6%		15.9%	14.0%	
Net income / loss	6,026	6,330	5.1%	6,961	7,248	4.1%	8,586	9,269	8.0%
margin	13.5%	14.1%		13.2%	12.5%		14.3%	12.4%	
EPS (in EUR, dil.)	0.40	0.41	2.5%	0.46	0.44	-5.3%	0.57	0.56	-1.9%

Source: First Berlin Equity Research, M1 Kliniken AG



Price target increased, Buy rating reiterated In our view, M1 is well positioned to capitalise on the rapidly growing beauty market. In recent years, the company has demonstrated the ability to grow sales strongly and deliver attractive profitability. Moreover, the sustainable business model and an attractive dividend payout (€0.27 per share, 2.4% 2017E dividend yield), make the company an appealing investment in the current low interest rate environment. Changes to our ten factor risk model based on the positive H1/17 performance cause us to reduce our WACC estimate for M1 from 12% to 10.5%. This reduction combined with our upgraded estimates generate a new price target of €16.50 (previously: €10.80). We reiterate our Buy recommendation.

VALUATION MODEL

Figure 3: DCF Model

All figures in EUR '000		2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E
Net sales		44,764	58,193	74,488	90,875	104,506	119,659	137,010	156,876
NOPLAT		4,544	5,698	7,508	9,422	11,738	14,560	17,658	20,783
+ depreciation & amortisation		313	349	447	545	627	718	822	941
Net operating cash flow		4,858	6,047	7,955	9,967	12,365	15,278	18,480	21,724
- total investments (CAPEX and WC)		-312	-3,259	-4,122	-3,277	-2,781	-2,484	-3,550	-3,749
Capital expenditures		-2,663	-2,008	-2,495	-1,954	-1,933	-1,974	-1,987	-1,961
Working capital		2,351	-1,251	-1,626	-1,323	-847	-510	-1,563	-1,788
Free cash flows (FCF)		4,546	2,788	3,834	6,691	9,584	12,794	14,930	17,975
PV of FCF's		4,473	2,483	3,089	4,879	6,326	7,642	8,070	8,793

All figures in EUR '000	
PV of FCFs in explicit period	109,538
PV of FCFs in terminal period	138,461
Enterprise value (EV)	247,999
+ Net cash / - net debt	24,173
+ Investments / minority interests	0
Shareholder value	272,172

Fair value per share in EUR		16.50
-----------------------------	--	-------

		Terminal growth rate								
			0.5%	1.0%	1.5%	2.0%	2.5%	3.0%	3.5%	
WACC	Cost of equity	10.5%	7.5%	24.42	25.72	27.25	29.09	31.34	34.15	37.76
	Pre-tax cost of debt	5.0%	8.5%	20.40	21.26	22.25	23.41	24.78	26.42	28.43
	Tax rate	28.0%	9.5%	17.39	17.98	18.65	19.42	20.31	21.35	22.57
	After-tax cost of debt	3.6%	10.5%	15.07	15.49	15.96	16.50	17.10	17.79	18.58
	Share of equity capital	100.0%	11.5%	13.23	13.54	13.89	14.26	14.69	15.17	15.71
	Share of debt capital	0.0%	12.5%	11.76	11.99	12.24	12.52	12.83	13.17	13.55
	WACC	10.5%	13.5%	10.55	10.73	10.92	11.12	11.35	11.60	11.87

*Please note our model runs through 2030 and we have only shown the abbreviated version for formatting purposes

Source: First Berlin Equity Research



INCOME STATEMENT

All figures in EUR '000	2014	2015	2016	2017E	2018E	2019E
Revenues	23,017	34,926	35,955	44,764	58,193	74,488
Change in inventory	-947	13	0	0	0	0
Other operating income	3,568	446	5,428	2,000	1,000	1,000
Cost of goods sold	-18,793	-24,602	-27,939	-28,724	-35,916	-45,693
Gross profit	6,845	10,782	13,444	18,040	23,277	29,795
Personnel expenses	-873	-1,570	-3,802	-6,715	-8,845	-11,024
Other operating expenses	-844	-1,978	-4,989	-4,700	-6,168	-7,896
Depreciation & amortisation	-111	-219	-288	-313	-349	-447
Operating income (EBIT)	5,016	7,015	4,364	6,312	7,914	10,428
Net financial result	-187	-245	1,124	1,136	1,146	1,158
Pre-tax income (EBT)	4,830	6,770	5,489	7,447	9,061	11,586
Tax result	-245	-140	-481	-1,117	-1,812	-2,317
Minority interests	0	0	0	0	0	0
Net income / loss	4,585	6,630	5,007	6,330	7,248	9,269
Diluted EPS (in €)	0.31	0.44	0.33	0.41	0.44	0.56
EBITDA	5,127	7,234	4,652	6,625	8,263	10,875
Ratios						
Gross margin	29.7%	30.9%	37.4%	40.3%	40.0%	40.0%
EBIT margin on revenues	21.8%	20.1%	12.1%	14.1%	13.6%	14.0%
EBITDA margin on revenues	22.3%	20.7%	12.9%	14.8%	14.2%	14.6%
Net margin on revenues	19.9%	19.0%	13.9%	14.1%	12.5%	12.4%
Tax rate	5.0%	2.0%	8.7%	15.0%	20.0%	20.0%
Expenses as % of revenues						
Personnel costs	3.8%	4.5%	10.6%	15.0%	15.2%	14.8%
Other operating expenses	3.7%	5.7%	13.9%	10.5%	10.6%	10.6%
Depreciation & amortisation	0.5%	0.6%	0.8%	0.7%	0.6%	0.6%
Y-Y Growth						
Revenues	278.5%	51.7%	2.9%	24.5%	30.0%	28.0%
Operating income	n.m.	39.8%	-37.8%	44.6%	25.4%	31.8%
Net income/ loss	n.m.	44.6%	-24.5%	26.4%	14.5%	27.9%



BALANCE SHEET

All figures in EUR '000	2014	2015	2016	2017E	2018E	2019E
Assets						
Current assets, total	7,536	19,605	16,995	35,639	37,662	41,163
Cash and cash equivalents	2,398	413	5,812	24,173	24,066	24,776
Short-term investments	2,031	6	2,704	2,785	2,869	2,955
Receivables	1,927	15,655	6,841	4,906	6,058	7,551
Inventories	974	3,181	1,410	3,541	4,428	5,633
Other current assets	206	351	227	234	241	248
Non-current assets, total	31,169	13,582	15,192	17,542	19,201	21,249
Property, plant & equipment	634	447	1,034	3,317	4,947	6,958
Goodwill & other intangibles	14,067	8,042	8,155	8,223	8,252	8,289
Financial assets	3,326	5,064	5,882	5,882	5,882	5,882
Other assets	13,141	29	120	120	120	120
Total assets	38,704	33,187	32,186	53,181	56,862	62,412
Shareholders' equity & debt						
Current liabilities, total	10,112	3,425	1,925	4,588	5,521	6,751
Short-term debt	1,184	16	14	0	0	0
Accounts payable	991	2,764	601	3,148	3,936	5,008
Accruals	1,080	138	669	736	810	891
Other current liabilities	6,857	507	640	704	775	852
Long-term liabilities, total	3,199	13	4	5	5	6
Long-term debt	837	0	0	0	0	0
Deferred revenue	0	0	0	0	0	0
Other liabilities	2,362	13	4	5	5	6
Minority interests	0	0	0	0	0	0
Shareholders' equity	25,394	29,750	30,257	48,588	51,336	55,655
Total consolidated equity and debt	38,704	33,187	32,186	53,181	56,862	62,412
Ratios						
Current ratio (x)	0.7	5.7	8.8	7.8	6.8	6.1
Quick ratio (x)	0.6	4.8	8.1	7.0	6.0	5.3
Net debt/(net cash)	-377	-396	-5,798	-24,173	-24,066	-24,776
Net gearing	-1.5%	-1.3%	-19.2%	-49.8%	-46.9%	-44.5%
Book value per share (in €)	n/a	1.98	2.02	3.16	3.11	3.37
Return on equity (ROE)	18.1%	22.3%	16.5%	13.0%	14.1%	16.7%



CASH FLOW STATEMENT

All figures in EUR '000	2014	2015	2016E	2017E	2018E	2019E
Net income	4,585	6,630	5,007	6,330	7,248	9,269
Depreciation and amortisation	111	219	288	313	349	447
Tax expense	243	138	476	1,117	1,812	2,317
Changes in working capital	-615	-3,448	7,788	2,395	-1,197	-1,560
Other adjustments	-3,506	-3,569	-4,465	0	0	0
Net interest result	185	245	-1,126	-1,136	-1,146	-1,158
Operating cash flow	1,003	214	7,969	9,020	7,066	9,315
Tax paid	37	-141	-32	-1,117	-1,812	-2,317
Interest income	0	24	140	151	163	176
Net operating cash flow	1,039	97	8,077	8,054	5,417	7,174
CapEx	-147	-678	-989	-2,663	-2,008	-2,495
Other investments and disposals	-6,853	1,283	2,826	999	999	999
Cash flow from investing	-7,000	605	1,838	-1,664	-1,009	-1,496
Free cash flow	-5,961	702	9,914	6,389	4,408	5,678
Debt financing, net	2,018	-2,013	-2	-14	0	0
Equity financing, net	5,690	0	0	16,500	0	0
Paid dividend	0	0	-4,500	-4,500	-4,500	-4,950
Interest expense	-126	-270	-13	-14	-16	-18
Cash flow from financing	7,582	-2,283	-4,515	11,972	-4,516	-4,968
Consolidation adjustments	167	-405	0	0	0	0
Net cash flow	1,789	-1,985	5,399	18,361	-107	710
Cash, start of the year	609	2,398	413	5,812	24,173	24,066
Cash, end of the year	2,398	413	5,812	24,173	24,066	24,776
EBITDA/share (in €)	0.34	0.48	0.31	0.43	0.50	0.66
Y-Y Growth						
Operating cash flow	n.m.	-78.6%	3616.9%	13.2%	-21.7%	31.8%
Free cash flow	n.m.	n.m.	1311.5%	-35.6%	-31.0%	28.8%
EBITDA/share	n.m.	41.1%	-35.7%	38.9%	16.2%	31.6%

FIRST BERLIN RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	11 August 2016	€8.10	ADD	€9.00
...	↓	↓	↓	↓
2	6 September 2016	€8.00	ADD	€9.00
3	9 May 2017	€8.40	BUY	€10.80
4	Today	€11.40	BUY	€16.50

Authored by: Christian Orquera, Analyst

Company responsible for preparation:

First Berlin Equity Research GmbH

Mohrenstraße 34
10117 Berlin

Tel. +49 (0)30 - 80 93 96 93 Fax +49 (0)30 - 80 93 96 87

info@firstberlin.com
www.firstberlin.com

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright© 2017 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 34B OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO THE GERMAN ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS [FINANV]

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular the German Securities Trading Act [WpHG], Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and the German Ordinance on the Analysis of Financial Instruments [FinAnV] into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with Section 34b Paragraph 1 of the German Securities Trading Act [WpHG] and Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) financial analyses may only be passed on or publicly distributed if circumstances or relations which may cause conflicts of interest among the authors, the legal entities responsible for such preparation or companies associated with them are disclosed along with the financial analysis.

First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest (further information and data may be provided on request):

- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

If despite these measures one or more of the aforementioned conflicts of interest cannot be avoided on the part of the author or First Berlin, then reference shall be made to such conflict of interest.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

STRONG BUY: An expected favourable price trend of more than 50% combined with sizeable confidence in the quality and forecast security of management.

BUY: An expected favourable price trend of more than 25% percent.

ADD: An expected favourable price trend of between 0% and 25%.

REDUCE: An expected negative price trend of between 0% and -15%.

SELL: An expected negative price trend of more than -15%.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: <http://firstberlin.com/disclaimer-english-link/>

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Lurgiallee 12, 60439 Frankfurt

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA, Canada and/or the United Kingdom (Great Britain).